Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (194) 194
index medicus (130) 130
male (120) 120
infectious diseases (114) 114
female (111) 111
adult (110) 110
hiv (88) 88
hiv infections - drug therapy (87) 87
middle aged (81) 81
hiv infections - complications (67) 67
immunology (65) 65
hepatitis c (62) 62
gastroenterology & hepatology (58) 58
hepatitis c virus (54) 54
antiviral agents - therapeutic use (50) 50
hepatitis (49) 49
risk factors (47) 47
microbiology (44) 44
cirrhosis (41) 41
drug therapy, combination (41) 41
hepacivirus - genetics (41) 41
hcv (40) 40
human-immunodeficiency-virus (39) 39
hepatitis c, chronic - drug therapy (38) 38
virology (37) 37
cd4 lymphocyte count (36) 36
infections (36) 36
treatment outcome (36) 36
antiretroviral therapy (35) 35
antiviral agents (34) 34
aged (33) 33
hepatitis c - complications (33) 33
ribavirin (33) 33
cohort studies (32) 32
genotype (32) 32
health aspects (32) 32
hepatitis c, chronic - complications (32) 32
liver (32) 32
viral load (32) 32
human immunodeficiency virus--hiv (31) 31
care and treatment (30) 30
anti-hiv agents - therapeutic use (29) 29
gastroenterology and hepatology (28) 28
hiv infections - virology (28) 28
italy (28) 28
ribavirin - therapeutic use (28) 28
therapy (28) 28
drug therapy (27) 27
mortality (27) 27
hepatitis c - drug therapy (24) 24
hiv infections - immunology (24) 24
interferon-alpha - therapeutic use (24) 24
patients (24) 24
aids (23) 23
analysis (23) 23
infection (23) 23
liver diseases (23) 23
research (23) 23
rna, viral - blood (23) 23
comorbidity (22) 22
disease progression (22) 22
fibrosis (22) 22
hepatitis b (22) 22
hepatitis-c virus (22) 22
highly active antiretroviral therapy (22) 22
hiv infection (22) 22
pharmacology & pharmacy (22) 22
sustained virological response (22) 22
coinfection (21) 21
interferon (21) 21
risk (21) 21
antiretroviral therapy, highly active (20) 20
epidemiology (20) 20
hepatitis c - virology (20) 20
rna (20) 20
adolescent (19) 19
hiv infections - epidemiology (19) 19
italy - epidemiology (19) 19
prevalence (19) 19
prospective studies (19) 19
anti-retroviral agents - therapeutic use (18) 18
antiretroviral drugs (18) 18
chronic hepatitis-c (18) 18
cohort (18) 18
hepatitis c, chronic - virology (18) 18
human immunodeficiency virus (18) 18
liver cirrhosis (18) 18
antiretroviral agents (17) 17
hiv-infected patients (17) 17
incidence (17) 17
infected patients (17) 17
liver transplantation (17) 17
polyethylene glycols - therapeutic use (17) 17
retrospective studies (17) 17
tenofovir (17) 17
virus-infection (17) 17
young adult (17) 17
hepacivirus (16) 16
hepatitis b - complications (16) 16
medicine (16) 16
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis
by Ascione, Antonio and De Luca, Massimo and Melazzini, Mario and Montilla, Simona and Trotta, Maria Paola and Petta, Salvatore and Puoti, Massimo and Sangiovanni, Vincenzo and Messina, Vincenzo and Bruno, Savino and Izzi, Antonio and Villa, Erica and Aghemo, Alessio and Zignego, Anna Linda and Orlandini, Alessandra and Fontanella, Luca and Gasbarrini, Antonio and Marzioni, Marco and Giannini, Edoardo G and Craxì, Antonio and ABACUS Study Group and For the ABACUS Study Group
Infection, ISSN 0300-8126, 10/2018, Volume 46, Issue 5, pp. 607 - 615
To analyse safety and efficacy of treatment based on ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in the sub-group of GT1 patients older than... 
Cirrhosis | Ombitasvir | Medicine & Public Health | General Practice / Family Medicine | Infectious Diseases | Internal Medicine | Paritaprevir | Elderly | Dasabuvir | Humans | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | Carbamates - administration & dosage | Hepatitis C, Chronic - complications | Uracil - administration & dosage | Ribavirin - administration & dosage | Aged, 80 and over | Female | Drug Therapy, Combination | Liver Cirrhosis - etiology | Liver Cirrhosis - diagnosis | Ritonavir - administration & dosage | Antiviral Agents - therapeutic use | Genotype | Treatment Outcome | Hepatitis C, Chronic - diagnosis | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Anilides - administration & dosage | Antiviral Agents - adverse effects | Biomarkers | Aged | Macrocyclic Compounds - administration & dosage | Sulfonamides - administration & dosage | Uracil - analogs & derivatives | Complications and side effects | Research | Hepatitis C | Drug therapy | Liver cirrhosis | Risk factors | Hypertension | Effectiveness | Liver diseases | Ritonavir | Health risks | Viruses | Pharmacology | Bilirubin | Multivariate analysis | Ribonucleic acid--RNA | Patients | Ribavirin | Hepatitis | Patient safety | Safety | Hepatitis C virus | Genotypes
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Multiclass HCV resistance to direct‐acting antiviral failure in real‐life patients advocates for tailored second‐line therapies
by Di Maio, Velia C and Cento, Valeria and Lenci, Ilaria and Aragri, Marianna and Rossi, Piera and Barbaliscia, Silvia and Melis, Michela and Verucchi, Gabriella and Magni, Carlo F and Teti, Elisabetta and Bertoli, Ada and Antonucci, FrancescoPaolo and Bellocchi, Maria C and Micheli, Valeria and Masetti, Chiara and Landonio, Simona and Francioso, Simona and Santopaolo, Francesco and Pellicelli, Adriano M and Calvaruso, Vincenza and Gianserra, Laura and Siciliano, Massimo and Romagnoli, Dante and Cozzolongo, Raffaele and Grieco, Antonio and Vecchiet, Jacopo and Morisco, Filomena and Merli, Manuela and Brancaccio, Giuseppina and Di Biagio, Antonio and Loggi, Elisabetta and Mastroianni, Claudio M and Pace Palitti, Valeria and Tarquini, Pierluigi and Puoti, Massimo and Taliani, Gloria and Sarmati, Loredana and Picciotto, Antonino and Vullo, Vincenzo and Caporaso, Nicola and Paoloni, Maurizio and Pasquazzi, Caterina and Rizzardini, Giuliano and Parruti, Giustino and Craxì, Antonio and Babudieri, Sergio and Andreoni, Massimo and Angelico, Mario and Perno, Carlo F and Ceccherini‐Silberstein, Francesca and Mariani, R and Iapadre, N and Grimaldi, A and Cozzolongo, R and Andreone, P and Verucchi, G and Menzaghi, B and Quirino, T and Pisani, V and Torti, C and Vecchiet, J and Bruzzone, B and De Maria, A and Marenco, S and Nicolini, L.A and Viscoli, C and Casinelli, K and Delle Monache, M and Lichtner, M and Aghemo, A and Boccaccio, V and Bruno, S and Cerrone, M and Colombo, M and D'Arminio Monforte, A and Danieli, E and Donato, F and Gubertini, G and Lleo, A and Magni, C.F and Mancon, A and Monico, S and Niero, F and Russo, M.L and Gnocchi, M and Orro, A and Milanesi, L and Baldelli, E and Bertolotti, M and Borghi, V and Mussini, C and Brancaccio, G and Gaeta, G.B and Lembo, V and Sangiovanni, V and Di Marco, V and Mazzola, A and Petta, S and D'Amico, E and Cacciatore, P and ... and HCV Italian Resistance Network Stu and HCV Italian Resistance Network Study Group and the HCV Italian Resistance Network Study Group
Liver International, ISSN 1478-3223, 04/2017, Volume 37, Issue 4, pp. 514 - 528
See Editorial on Page 506 
hepatitis C virus | direct‐acting antivirals | resistance test | antiviral therapy | resistance‐associated substitutions | resistance-associated substitutions | direct-acting antivirals | LONG-TERM PERSISTENCE | VARIANTS | SOFOSBUVIR | RIBAVIRIN | GENOTYPE 1 | TREATMENT-NAIVE | HEPATITIS-C VIRUS | NS5A | INFECTION | RETREATMENT | GASTROENTEROLOGY & HEPATOLOGY | Hepacivirus - drug effects | Sofosbuvir - therapeutic use | Recurrence | Antiviral Agents - therapeutic use | Humans | Middle Aged | Ribavirin - therapeutic use | Hepacivirus - genetics | Viral Nonstructural Proteins - genetics | Genotype | Male | Interferons - therapeutic use | Hepatitis C, Chronic - drug therapy | Sequence Analysis, DNA | Drug Resistance, Viral - genetics | Treatment Failure | Female | Italy | Aged | Mutation | Sustained Virologic Response | Drug Therapy, Combination | Care and treatment | Interferon | Biological response modifiers | Hepatitis C virus | Hepatitis C | Analysis | Medical research | Failure analysis | Genes | Clinical trials | Patients | Failure | Ribavirin
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection
by Afdhal, Nezam and Zeuzem, Stefan and Kwo, Paul and Chojkier, Mario and Gitlin, Norman and Puoti, Massimo and Romero-Gomez, Manuel and Zarski, Jean-Pierre and Agarwal, Kosh and Buggisch, Peter and Foster, Graham R and Bräu, Norbert and Buti, Maria and Jacobson, Ira M and Subramanian, G. Mani and Ding, Xiao and Mo, Hongmei and Yang, Jenny C and Pang, Phillip S and Symonds, William T and McHutchison, John G and Muir, Andrew J and Mangia, Alessandra and Marcellin, Patrick and ION-1 Investigators
The New England Journal of Medicine, ISSN 0028-4793, 05/2014, Volume 370, Issue 20, pp. 1889 - 1898
In this trial, previously untreated patients with hepatitis C virus genotype 1 infection were randomly assigned to 12 or 24 weeks of ledipasvir and sofosbuvir,... 
MEDICINE, GENERAL & INTERNAL | TELAPREVIR | THERAPY | HEPATITIS | BOCEPREVIR | RIBAVIRIN | COMBINATION | Humans | Middle Aged | Drug Resistance, Viral | Fluorenes - therapeutic use | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | RNA, Viral - blood | Viral Load | Young Adult | Aged, 80 and over | Adult | Female | Fluorenes - adverse effects | Uridine Monophosphate - adverse effects | Benzimidazoles - adverse effects | Drug Therapy, Combination | Benzimidazoles - therapeutic use | Uridine Monophosphate - therapeutic use | Drug Administration Schedule | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Genotype | Hepatitis C, Chronic - drug therapy | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Uridine Monophosphate - analogs & derivatives | Adolescent | Aged | Sofosbuvir | Headache | Chronic infection | Fatigue | Infections | Nausea | Patients | Ribavirin | Cirrhosis | Sleep disorders | Genotype & phenotype | Hepatitis | Interferon | Hepatitis C | Drug therapy | Genotypes | Medicaments antivírics | Antiviral agents | Hepatitis C virus | Virus de l'hepatitis C | Life Sciences
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens
by Cento, Valeria and Nguyen, Thi Huyen Tram and Di Carlo, Domenico and Biliotti, Elisa and Gianserra, Laura and Lenci, Ilaria and Di Paolo, Daniele and Calvaruso, Vincenza and Teti, Elisabetta and Cerrone, Maddalena and Romagnoli, Dante and Melis, Michela and Danieli, Elena and Menzaghi, Barbara and Polilli, Ennio and Siciliano, Massimo and Nicolini, Laura Ambra and Di Biagio, Antonio and Magni, Carlo Federico and Bolis, Matteo and Antonucci, Francesco Paolo and Di Maio, Velia Chiara and Alfieri, Roberta and Sarmati, Loredana and Casalino, Paolo and Bernardini, Sergio and Micheli, Valeria and Rizzardini, Giuliano and Parruti, Giustino and Quirino, Tiziana and Puoti, Massimo and Babudieri, Sergio and Monforte, Antonella D'Arminio and Andreoni, Massimo and Craxì, Antonio and Angelico, Mario and Pasquazzi, Caterina and Taliani, Gloria and Guedj, Jeremie and Perno, Carlo Federico and Ceccherini-Silberstein, Francesca
PLoS ONE, ISSN 1932-6203, 05/2017, Volume 12, Issue 5, p. e0177352
Background Intracellular HCV-RNA reduction is a proposed mechanism of action of direct-acting antivirals (DAAs), alternative to hepatocytes elimination by... 
PROTEASE INHIBITOR | INTERFERON-ALPHA | TELAPREVIR | HEPATITIS-C VIRUS | MULTIDISCIPLINARY SCIENCES | TREATMENT-EXPERIENCED PATIENTS | TRIPLE THERAPY | ALANINE AMINOTRANSFERASE | INFECTED-CELLS | RIBAVIRIN | DYNAMICS IN-VIVO | Hepatitis C - drug therapy | Humans | Middle Aged | Hepacivirus - genetics | Male | RNA, Viral - blood | Alanine Transaminase - blood | Simeprevir - administration & dosage | Ribavirin - administration & dosage | Female | Drug Therapy, Combination | Antiviral Agents - pharmacology | Sofosbuvir - pharmacology | Administration, Oral | Interferons - pharmacology | Treatment Outcome | Antiviral Agents - administration & dosage | Simeprevir - pharmacology | Sofosbuvir - administration & dosage | Aged | Oligopeptides - administration & dosage | Alanine Transaminase - metabolism | Kinetics | Oligopeptides - pharmacology | Viral Nonstructural Proteins - antagonists & inhibitors | Ribavirin - pharmacology | Care and treatment | RNA | Dynamics | Interferon | Alanine aminotransferase | Research | Drug therapy | Hepatitis C | Liver cirrhosis | Syngeneic grafts | Liver | Proteinase | Antiinfectives and antibacterials | Tropical diseases | Hepatitis | Genotype & phenotype | Surgery | Damage | Liver diseases | Mortality | Cirrhosis | Chemotherapy | Hospitals | Infectious diseases | Inhibitors | Hepatocytes | Adults | Clinical medicine | Liver transplantation | Drugs | Health sciences | Microbiology | Medical services | Population studies | Viruses | Transplantation | Infections | Immunosuppressive agents | Biomedical materials | Reduction | Hepatology | Gastroenterology | Mathematical models | Clinical microbiology | Enzyme-linked immunosorbent assay | CpG islands | Antiviral agents | Alanine | Receiving | Health | Markers | Antimicrobial agents | Pharmacology | Ribonucleic acid--RNA | Medicine | Cell death | Decay | Ribonucleic acid
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy
by Bertoli, Ada and Sorbo, Maria Chiara and Aragri, Marianna and Lenci, Ilaria and Teti, Elisabetta and Polilli, Ennio and Di Maio, Velia Chiara and Gianserra, Laura and Biliotti, Elisa and Masetti, Chiara and Magni, Carlo F and Babudieri, Sergio and Nicolini, Laura A and Milana, Martina and Cacciatore, Pierluigi and Sarmati, Loredana and Pellicelli, Adriano and Paolucci, Stefania and Craxì, Antonio and Morisco, Filomena and Palitti, Valeria Pace and Siciliano, Massimo and Coppola, Nicola and Iapadre, Nerio and Puoti, Massimo and Rizzardini, Giuliano and Taliani, Gloria and Pasquazzi, Caterina and Andreoni, Massimo and Parruti, Giustino and Angelico, Mario and Perno, Carlo Federico and Cento, Valeria and Ceccherini-Silberstein, Francesca and Andreone, Pietro and Baldanti, Fausto and Barbarini, Giorgio and Boccaccio, Vincenzo and Boglione, Lucio and Bolis, Matteo and Bonora, Stefano and Borghi, Vanni and Brancaccio, Giuseppina and Bruno, Savino and Bruzzone, Bianca and Calvaruso, Vincenza and Caporaso, Nicola and Ciaccio, Antonio and Ciancio, Alessia and Colombatto, Piero and Cozzolongo, Raffaele and D'Ambrosio, Cecilia and D'Ettorre, Gabriella and De Leonardis, Francesco and De Luca, Andrea and Di Biagio, Antonio and Di Perri, Giovanni and Francioso, Simona and Gaeta, Giovanni Battista and Gasbarrini, Antonio and Ghisetti, Valeria and Giorgini, Alessia and Grieco, Antonio and Gubertini, Guido and Gulminetti, Roberto and Lambiase, Lara and Landonio, Simona and Lichtner, Miriam and Maida, Ivana and Marenco, Simona and Marinaro, Letizia and Maserati, Renato and Melis, Michela and Menzaghi, Barbara and Meregalli, Elisa and Micheli, Valeria and Niero, Fosca and Paoloni, Maurizio and Pieri, Alessandro and Rendina, Maria and Romagnoli, Dante and Rossetti, Barbara and Ruggiero, Tina and Sangiovanni, Vincenzo and Starace, Mario and Sticchi, Laura and Tarquini, Pierluigi and Toniutto, Pierluigi and Vullo, Vincenzo and Zazzi, Maurizio and Hcv Virology Italian Resistance Ne and HCV Virology Italian Resistance Network (VIRONET-C)
Scientific Reports, ISSN 2045-2322, 12/2018, Volume 8, Issue 1, pp. 8988 - 11
Natural resistance-associated substitutions (RASs) are reported with highly variable prevalence across different HCV genotypes (GTs). Frequency of natural RASs... 
GLECAPREVIR | TREATMENT-NAIVE | REAL-LIFE | PIBRENTASVIR | CIRRHOSIS | MULTIDISCIPLINARY SCIENCES | SIMEPREVIR PLUS SOFOSBUVIR | RESPONSE RATES | DIRECT-ACTING ANTIVIRALS | 1 INFECTION | OPEN-LABEL | Hepatitis C | Disease resistance | Genotypes
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Current and future challenges in HCV: insights from an Italian experts panel
by Andreoni, Massimo and Babudieri, Sergio and Bruno, Savino and Colombo, Massimo and Zignego, Anna L and Di Marco, Vito and Di Perri, Giovanni and Perno, Carlo F and Puoti, Massimo and Taliani, Gloria and Villa, Erica and Craxì, Antonio
Infection, ISSN 0300-8126, 4/2018, Volume 46, Issue 2, pp. 147 - 163
The recent availability of direct acting antiviral drugs (DAAs) has drastically changed hepatitis C virus (HCV) treatment scenarios, due to the exceedingly... 
DAAs | Treatment | Medicine & Public Health | Comorbidities | General Practice / Family Medicine | Infectious Diseases | Internal Medicine | HCV | INFECTIOUS DISEASES | HUMAN-IMMUNODEFICIENCY-VIRUS | PATIENT-REPORTED OUTCOMES | SUSTAINED VIROLOGICAL RESPONSE | KIDNEY-TRANSPLANT RECIPIENTS | HEPATITIS-C VIRUS | TREATMENT-EXPERIENCED PATIENTS | RESISTANCE-ASSOCIATED SUBSTITUTIONS | GENOTYPE 1 INFECTION | FIXED-DOSE COMBINATION | INTERFERON PLUS RIBAVIRIN | Hepatitis C virus | Comorbidity | Care and treatment | Health care | Hepatitis | Antiviral agents | Medical research | Liver | Medical treatment | Viruses | Disease management | Hepatitis C | Antiviral drugs
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update December 2014
by Antinori, Andrea and Marcotullio, Simone and Andreoni, Massimo and Ammassari, Adriana and Monforte, Antonella D'arminio and Galli, Massimo and Girardi, Enrico and Mazzotta, Francesco and Mussini, Cristina and Puoti, Massimo and Lazzarin, Adriano and Adriana, Ammassari and Gioacchino, Angarano and Orlando, Armignacco and Sergio, Babudieri and Teresa, Bini and Paolo, Bonfanti and Stefano, Bonora and Marco, Borderi and Michele, Breveglieri and Raffaele, Bruno and Rosaria, Capobianchi Maria and Roberto, Cagarelli and Emilia-Romagna, Regione and Andrea, Calcagno and Antonella, Castagna and Francesco, Castelli and Maria, Cattelan Anna and Roberto, Cauda and Alessandra, Cerioli and Antonio, Chirianni and Antonella, Cingolani and Paola, Cinque and Maria, Corbelli Giulio and Antonella, D'arminio Monforte and Gabriella, D'ettorre and Gabriella, De Carli and Andrea, De Luca and Antonio, Di Biagio and Giovanni, Di Perri and Massimo, Di Pietro and Issa, El Hamad and Margherita, Errico and Carola, Finarelli Alba and Raffaele, Ospedale San and Carlo, Milano Giaquinto and Gerardo, Ospedale San and Battista, Gaeta Giovanni and Cristina, Gervasoni and Massimo, Galli and Vania, Giacomet and Nicola, Gianotti and Enrico, Girardi and Andrea, Gori and Paolo, Grossi and Giovanni, Guaraldi and Jelena, Ivanovic and Miriam, Lichtner and Giuseppina, Liuzzi and Sergio, Lo Caputo and Paolo, Maggi and Franco, Maggiolo and Marina, Malena and Giulia, Marchetti and Renato, Maserati and Claudio, Mastroianni and Alberto, Matteelli and Francesco, Mazzotta and Cristina, Mussini and Emanuele, Nicastri and Silvia, Nozza and Massimo, Oldrini and Grazia, Pascucci Maria and Carlo-Federico, Perno and Tullio, Prestileo and Massimo, Puoti and Vincenzo, Puro and Laura, Rancilio and Marina, Ravizza and Ospedaliera, Azienda and Giuliano, Rizzardini and Stefano, Rusconi and Maria, Santoro and Laura, Sighinolfi and Maria, Stagnitta and Giulio, Starnini and Enrica, Tamburrini and Giuseppe, Tambussi and Marcello, Tavio and Carlo, Torti and Emanuela, Vaccher and Claudio, Viscoli and Raffaele, Visintini and Vincenzo, Vullo and Mauro, Zaccarelli and Vincenzo, Zuccotti Gian and Italian HIV Guidelines Working Grp and Italian HIV Guidelines Working Group
New Microbiologica, ISSN 1121-7138, 07/2015, Volume 38, Issue 3, pp. 299 - 327
TENOFOVIR DISOPROXIL FUMARATE | REVERSE-TRANSCRIPTASE INHIBITORS | ONCE-DAILY DOLUTEGRAVIR | HEPATITIS-C VIRUS | NON-INFERIORITY TRIAL | MICROBIOLOGY | SINGLE-TABLET REGIMEN | RANDOMIZED CONTROLLED-TRIAL | TREATMENT-NAIVE PATIENTS | HIV-INFECTED PATIENTS | RITONAVIR-BOOSTED ATAZANAVIR | HIV-1 - physiology | HIV-1 - drug effects | HIV Infections - diagnosis | HIV Infections - virology | Humans | Anti-HIV Agents - therapeutic use | HIV Infections - drug therapy | Italy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study
by Molina, Jean-Michel, Prof and Orkin, Chloe, MD and Iser, David M, MBBS and Zamora, Francisco-Xavier, MD and Nelson, Mark, MBBS and Stephan, Christoph, Prof and Massetto, Benedetta, MD and Gaggar, Anuj, MD and Ni, Liyun, MA and Svarovskaia, Evguenia, PhD and Brainard, Diana, MD and Subramanian, G Mani, MD and McHutchison, John G, MD and Puoti, Massimo, Prof and Rockstroh, Jürgen K, Prof and PHOTON-2 Study Team and PHOTON-2 study team
Lancet, The, ISSN 0140-6736, 2015, Volume 385, Issue 9973, pp. 1098 - 1106
Summary Background Although interferon-free regimens are approved for patients co-infected with HIV and genotype-2 or genotype-3 hepatitis C virus (HCV),... 
Internal Medicine | GENOTYPE 1 | TRIAL | BILIRUBIN | MEDICINE, GENERAL & INTERNAL | THERAPY | CIRRHOSIS | PEGYLATED-INTERFERON | COINFECTION | HCV | ATAZANAVIR | Liver Cirrhosis - etiology | Antiviral Agents - therapeutic use | Coinfection - drug therapy | Humans | Middle Aged | Ribavirin - therapeutic use | Hepacivirus - genetics | Male | RNA, Viral - blood | Treatment Outcome | Hepatitis C, Chronic - complications | Hepatitis C, Chronic - drug therapy | Viral Load | Young Adult | Uridine Monophosphate - analogs & derivatives | Adolescent | HIV Infections - complications | Adult | Female | Aged | Drug Therapy, Combination | Sofosbuvir | Uridine Monophosphate - therapeutic use | Highly active antiretroviral therapy | Antiviral agents | HIV patients | Cross infection | Nosocomial infections | Biological response modifiers | Drug therapy | Hepatitis C virus | HIV (Viruses) | Health aspects | HIV infection | Ribavirin | Hepatitis | Antiretroviral drugs | Genotype & phenotype | Human immunodeficiency virus--HIV | Mortality
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text EASL Recommendations on Treatment of Hepatitis C 2018
by Pawlotsky, Jean-Michel and Negro, Francesco and Aghemo, Alessio and Berenguer, Marina and Dalgard, Olav and Dusheiko, Geoffrey and Marra, Fiona and Puoti, Massimo and Wedemeyer, Heiner and European Assoc Study Liver and European Association for the Study of the Liver and European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu
Journal of Hepatology, ISSN 0168-8278, 08/2018, Volume 69, Issue 2, pp. 461 - 511
Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with approximately 71 million chronically infected individuals worldwide. Clinical... 
SUSTAINED VIROLOGICAL RESPONSE | ACTING ANTIVIRAL THERAPY | SOFOSBUVIR PLUS RIBAVIRIN | TREATMENT-EXPERIENCED PATIENTS | OPIOID SUBSTITUTION THERAPY | VIRUS GENOTYPE 1 | HEPATOCELLULAR-CARCINOMA RECURRENCE | CHRONIC KIDNEY-DISEASE | GASTROENTEROLOGY & HEPATOLOGY | REAL-WORLD EFFECTIVENESS | CHRONIC VIRAL-HEPATITIS
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights